![]() |
市場調查報告書
商品編碼
1833575
2032年腸外抗生素市場預測:按藥物類別、活性頻譜、劑型、給藥途徑、適應症、最終用戶和地區進行的全球分析Parenteral Antibiotics Market Forecasts to 2032 - Global Analysis By Drug Class, Spectrum of Activity, Formulation Type, Route of Administration, Indication, End User and By Geography |
根據 Stratistics MRC 的數據,全球腸外抗生素市場預計在 2025 年達到 257.4 億美元,到 2032 年將達到 394.8 億美元,預測期內的複合年成長率為 6.3%。
腸外抗生素是指在消化器官系統外給藥的藥物,通常透過靜脈注射、肌肉注射或皮下注射。它們適用於緊急治療以及無法口服或胃腸道吸收不足的情況。這種方法將藥物直接輸送到血液中,從而具有更快的起效速度、更高的生物利用度,並能有效感染疾病需要即時干涉的嚴重或廣泛性感染疾病。
根據尼泊爾國家生物技術資訊中心 (NCBI) 2021 年 11 月發表的一項研究,2019 年尼泊爾腸外抗生素的總限定日劑量 (DDD) 達到 48,947.7,比 2017 年的 39,639.7 成長了 23%。
抗生素抗藥性(AMR)的蔓延
隨著病原體不斷進化並對傳統療法產生抗藥性,醫療保健提供者正轉向注射劑以獲得更快、更有效的治療效果。這一趨勢在醫院環境中尤其明顯,因為醫院環境中存在多重抗藥性感染。藥物輸送系統和製劑科學的技術進步正在提高腸外抗生素的有效性。精準醫療和特異性病原體的治療的興起進一步推動了市場成長。全球衛生組織也將降低抗生素抗藥性作為優先事項,並推動對新型抗生素和管理計畫的投資。
開發和商業化成本高
大規模臨床試驗、嚴格的安全規程以及遵守FDA和EMA法規等全球標準,導致開發週期更長、成本更高。脂質體和緩釋性等先進技術的採用,也讓核准流程更加複雜。規模較小的製藥公司往往面臨資源限制,這限制了其創新和擴大生產規模的能力。此外,低溫運輸物流和無菌包裝的需求也增加了營運成本。這些因素共同阻礙了藥物快速進入市場,並減緩了治療方法創新的步伐。
擴大門診腸外抗生素治療(OPAT)
門診腸外抗生素治療 (OPAT) 的推廣為市場開闢了新的成長途徑。 OPAT 允許患者在院外接受抗生素輸注,從而減輕住院負擔和醫療費用。攜帶式輸注設備和遠端監控技術的進步使 OPAT 更加便利和安全。醫療保健系統正在採用分散式照護模式,家庭治療越來越受歡迎。報銷改革和臨床指南正在支持將 OPAT 納入主流醫療。這種轉變推動了對易於使用、穩定、長效且專為門診病人設計的腸外抗生素製劑的需求。
與學名藥的競爭加劇
專利到期和生物相似藥開發的監管激勵措施正在加速學名藥的進入。學名藥學名藥蓬勃發展,加劇了競爭動態。為了維持市場佔有率,新藥公司必須投資生命週期管理策略,例如配方改進和聯合治療。
新冠疫情嚴重擾亂了腸外抗生素市場格局,改變了需求模式和供應鏈運作。儘管擇期手術被推遲,醫院抗生素使用量減少,但重症監護室(ICU)入院人數激增,導致頻譜注射劑的需求增加。生產延誤和全球物流瓶頸導致關鍵抗生素暫時短缺。然而,這場危機加速了數位醫療的普及,包括遠距處方和基於遠端醫療的OPAT計畫。監管機構推出了緊急途徑,以確保快速核准和藥品供應。疫情後的復甦目前專注於建立韌性供應鏈和擴展分散式醫療模式。
青黴素類藥物預計將成為預測期內最大的藥物
青黴素類抗生素因其廣泛的療效和成熟的臨床效用,預計將在預測期內佔據最大的市場佔有率。這些抗生素廣泛用於治療感染疾病、皮膚和尿道感染,尤其適用於住院患者。製劑穩定性和給藥便捷性的不斷改進鞏固了其市場領先地位。頻譜青黴素類抗生素與BETA-內醯胺酶抑制劑的聯合應用增強了抗藥性因應措施。青黴素類抗生素因其安全性和成本效益而受到醫院的青睞,尤其是在團體治療中。新興趨勢包括雙藥組合方案和納入OPAT方案。
預計門診手術中心部分在預測期內的複合年成長率最高
預計在預測期內,門診手術中心細分市場將實現最高成長率,這得益於手術全期。智慧型輸液系統與雲端基礎庫存追蹤的整合正在簡化抗生素的管理。優惠的報銷政策和更短的患者住院時間正在推動門診手術中心的利用率。向微創手術的轉變正在增加對速效注射抗生素的需求。緊湊型抗生素套件和單劑量包裝的創新正根據門診手術中心的工作流程進行客製化。
受醫療基礎設施擴張和感染率上升的推動,亞太地區預計將在預測期內佔據最大的市場佔有率。中國、印度和印尼等國家正在投資建立醫院容量和抗生素生產能力。政府推動本地生產和抗生素管理的措施正在推動市場擴張。該地區的都市區地區都正在迅速普及注射療法。全球製藥公司與本地公司之間的策略合作夥伴關係正在加強分銷和技術轉移。新興趨勢包括人工智慧診斷和服務欠缺地區的行動門診治療單位 (OPAT)。
在技術創新和強勁醫療支出的推動下,北美預計將在預測期內呈現最高的複合年成長率。美國和加拿大在新型腸外抗生素製劑(例如基於脂質體和奈米顆粒的注射劑)的開發方面處於領先地位。監管機構正在簡化重要抗生素的核准途徑,以加快其市場准入速度。醫院正在整合電子處方和智慧輸液泵,以最佳化抗生素給藥。該地區受益於強大的報銷框架和對抗菌藥物抗藥性挑戰的高度認知。隨著個人化醫療和門診治療的擴展,北美正處於抗生素創新的前沿。
According to Stratistics MRC, the Global Parenteral Antibiotics Market is accounted for $25.74 billion in 2025 and is expected to reach $39.48 billion by 2032 growing at a CAGR of 6.3% during the forecast period. Parenteral antibiotics refer to drugs given outside the digestive system, commonly via intravenous, intramuscular, or subcutaneous injection. They are preferred for urgent treatment, cases where oral intake is not feasible, or when gastrointestinal absorption is inadequate. This method delivers the medication directly into the bloodstream, providing rapid action, greater bioavailability, and effective management of serious or widespread infections requiring immediate intervention.
According to a study published in National Canter for Biotechnology Information (NCBI) in November 2021, in Nepal, the total defined daily dose (DDD) of parenteral antibiotics reached 48,947.7 in 2019 with an increase of 23% from 39,639.7 in 2017.
Growing antimicrobial resistance (AMR)
As pathogens evolve and become resistant to conventional treatments, healthcare providers are turning to injectable formulations for faster and more effective outcomes. This trend is especially pronounced in hospital settings where multidrug-resistant infections are prevalent. Technological advancements in drug delivery systems and formulation science are enhancing the efficacy of parenteral antibiotics. The rise of precision medicine and pathogen-specific therapies is further boosting market growth. Global health agencies are also prioritizing AMR mitigation, driving investment in novel antibiotic classes and stewardship programs.
High cost of development and commercialization
Extensive clinical trials, stringent safety protocols, and compliance with global standards like FDA and EMA regulations contribute to prolonged timelines and elevated costs. Incorporating advanced technologies such as liposomal delivery and extended-release mechanisms adds complexity to the approval process. Smaller pharmaceutical firms often face resource constraints, limiting their ability to innovate or scale production. Additionally, the need for cold chain logistics and sterile packaging increases operational expenses. These factors collectively hinder rapid market entry and slow down the pace of therapeutic innovation.
Growing outpatient parenteral antibiotic therapy (OPAT)
The expansion of outpatient parenteral antibiotic therapy (OPAT) is unlocking new growth avenues for the market. OPAT enables patients to receive intravenous antibiotics outside hospital settings, reducing inpatient burden and healthcare costs. Advances in portable infusion devices and remote monitoring technologies are making OPAT more accessible and safer. Healthcare systems are increasingly adopting decentralized care models, with home-based treatments gaining traction. Reimbursement reforms and clinical guidelines are supporting OPAT integration into mainstream care. This shift is driving demand for user-friendly, stable, and long-acting parenteral antibiotic formulations tailored for outpatient use.
Increased competition from generics
Patent expirations and regulatory incentives for biosimilar development are accelerating generic entry. While generics improve accessibility, they also compress profit margins for originator companies. Technological parity in manufacturing and formulation is narrowing the differentiation gap. Emerging markets are witnessing a surge in local generic production, intensifying competitive dynamics. To maintain market share, innovators must invest in lifecycle management strategies, such as reformulations and combination therapies.
The COVID-19 pandemic significantly disrupted the parenteral antibiotics landscape, altering demand patterns and supply chain operations. Elective procedures were postponed, reducing hospital-based antibiotic usage, while ICU admissions surged, increasing demand for broad-spectrum injectables. Manufacturing delays and global logistics bottlenecks led to temporary shortages of critical antibiotics. However, the crisis accelerated digital health adoption, including remote prescribing and telemedicine-based OPAT programs. Regulatory bodies introduced emergency pathways to fast-track approvals and ensure drug availability. Post-pandemic recovery is now focused on building resilient supply chains and expanding decentralized treatment models.
The penicillinssegment is expected to be the largest during the forecast period
The penicillinssegment is expected to account for the largest market share during the forecast period, due to its broad-spectrum efficacy and established clinical utility. These antibiotics are widely used in treating respiratory, skin, and urinary tract infections, especially in inpatient settings. Continuous improvements in formulation stability and dosing convenience are reinforcing their market leadership. The development of extended-spectrum penicillins and beta-lactamase inhibitor combinations is enhancing resistance management. Hospitals favor penicillins for their safety profile and cost-effectiveness, particularly in high-volume treatment scenarios. Emerging trends include dual-drug regimens and integration into OPAT protocols.
The ambulatory surgical centerssegment is expected to have the highest CAGR during the forecast period
Over the forecast period, the ambulatory surgical centerssegment is predicted to witness the highest growth rate, driven by the rise in outpatient procedures. ASCs are increasingly performing complex surgeries that require perioperative antibiotic prophylaxis. Integration of smart infusion systems and cloud-based inventory tracking is streamlining antibiotic administration. Favorable reimbursement policies and shorter patient stays are boosting ASC utilization. The shift toward minimally invasive techniques is increasing demand for rapid-acting injectable antibiotics. Innovations in compact antibiotic kits and single-dose packaging are tailored for ASC workflows.
During the forecast period, the Asia Pacificregion is expected to hold the largest market share, supported by expanding healthcare infrastructure and rising infection rates. Countries like China, India, and Indonesia are investing in hospital capacity and antibiotic manufacturing capabilities. Government initiatives promoting local production and antimicrobial stewardship are fueling market expansion. The region is witnessing rapid adoption of injectable therapies in both urban and rural settings. Strategic collaborations between global pharmaceutical firms and regional players are enhancing distribution and technology transfer. Emerging trends include AI-assisted diagnostics and mobile OPAT units in underserved areas.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, driven by technological innovation and robust healthcare spending. The U.S. and Canada are leading in the development of novel parenteral antibiotic formulations, including liposomal and nanoparticle-based injectables. Regulatory agencies are streamlining approval pathways for critical antibiotics, encouraging faster market entry. Hospitals are integrating electronic prescribing and smart infusion pumps to optimize antibiotic delivery. The region benefits from strong reimbursement frameworks and high awareness of AMR challenges. As personalized medicine and outpatient care expand, North America remains at the forefront of antibiotic innovation.
Key players in the market
Some of the key players in Parenteral Antibiotics Market include Pfizer Inc., Sandoz, Merck & Co., Inc., Spero Therapeutics, Johnson & Johnson, AstellasPharma Inc., GlaxoSmithKline plc, Entasis Therapeutics, Sanofi, F. Hoffmann-La Roche Ltd, Novartis AG, Bristol-Myers Squibb, Bayer AG, Eli Lilly and Company, and Abbott Laboratories.
In September2025, Pfizer Inc. and Metsera, Inc. announced the companies have entered into a definitive agreement under which Pfizer will acquire Metsera, a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. The acquisition brings deep expertise and a portfolio of differentiated oral and injectable incretin, non-incretin and combination therapy candidates with potential best-in-class efficacy and safety profiles.
In February2025, Shedd Aquarium and global healthcare company Abbott are announcing one of Shedd's largest corporate gifts in recent history a $10 million pledge from Abbott and Abbott's philanthropic foundation, Abbott Fund. The investment cements the longstanding partnership between Shedd, Abbott, and Abbott Fund to enrich the cultural, educational and environmental fabric of Chicago and spark passion for protecting the ocean environment.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.